Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuroendocrine Tumors | 9 | 2023 | 593 | 2.770 |
Why?
|
Pancreatic Neoplasms | 21 | 2023 | 5213 | 1.880 |
Why?
|
Intestinal Neoplasms | 3 | 2023 | 319 | 1.460 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2022 | 981 | 0.950 |
Why?
|
Paraganglioma | 2 | 2022 | 144 | 0.930 |
Why?
|
Pheochromocytoma | 2 | 2022 | 337 | 0.880 |
Why?
|
Carcinoma, Pancreatic Ductal | 9 | 2023 | 1607 | 0.870 |
Why?
|
Somatostatin | 3 | 2023 | 460 | 0.840 |
Why?
|
Hypoalbuminemia | 1 | 2023 | 86 | 0.840 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2022 | 735 | 0.710 |
Why?
|
Adenocarcinoma | 7 | 2023 | 6318 | 0.630 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 382 | 0.620 |
Why?
|
Stomach Neoplasms | 3 | 2023 | 1318 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 11410 | 0.570 |
Why?
|
Intestine, Small | 1 | 2021 | 1242 | 0.520 |
Why?
|
Endometrial Neoplasms | 1 | 2022 | 1351 | 0.420 |
Why?
|
Germ Cells | 3 | 2022 | 627 | 0.340 |
Why?
|
Leucovorin | 4 | 2021 | 618 | 0.340 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13635 | 0.320 |
Why?
|
Rectal Neoplasms | 1 | 2017 | 1192 | 0.310 |
Why?
|
Organoplatinum Compounds | 3 | 2017 | 409 | 0.290 |
Why?
|
Fluorouracil | 4 | 2021 | 1609 | 0.270 |
Why?
|
Diethylstilbestrol | 1 | 2005 | 89 | 0.270 |
Why?
|
Estrogens, Non-Steroidal | 1 | 2005 | 54 | 0.270 |
Why?
|
Albumins | 2 | 2023 | 563 | 0.210 |
Why?
|
Infertility, Male | 1 | 2005 | 408 | 0.210 |
Why?
|
Hypertension | 1 | 2022 | 8431 | 0.210 |
Why?
|
Americas | 1 | 2022 | 111 | 0.210 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 146 | 0.200 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 145 | 0.200 |
Why?
|
Cells | 1 | 2022 | 167 | 0.190 |
Why?
|
Atlases as Topic | 1 | 2022 | 235 | 0.190 |
Why?
|
Paclitaxel | 3 | 2023 | 1701 | 0.190 |
Why?
|
Helicobacter pylori | 1 | 2023 | 379 | 0.180 |
Why?
|
Helicobacter Infections | 1 | 2023 | 384 | 0.180 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2023 | 324 | 0.170 |
Why?
|
Edema | 1 | 2023 | 791 | 0.170 |
Why?
|
Germ-Line Mutation | 3 | 2021 | 1786 | 0.160 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3571 | 0.160 |
Why?
|
Neutropenia | 1 | 2023 | 888 | 0.160 |
Why?
|
Receptor, IGF Type 1 | 1 | 2020 | 390 | 0.150 |
Why?
|
RNA Splicing | 1 | 2022 | 904 | 0.150 |
Why?
|
Peritoneal Neoplasms | 1 | 2023 | 663 | 0.150 |
Why?
|
Organ Specificity | 1 | 2022 | 2004 | 0.150 |
Why?
|
Jews | 1 | 2019 | 385 | 0.150 |
Why?
|
Genetic Counseling | 1 | 2021 | 601 | 0.150 |
Why?
|
Humans | 35 | 2023 | 739398 | 0.140 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3508 | 0.130 |
Why?
|
Pregnancy Outcome | 1 | 2005 | 2789 | 0.130 |
Why?
|
Medical History Taking | 1 | 2019 | 782 | 0.130 |
Why?
|
Single-Cell Analysis | 2 | 2022 | 2141 | 0.130 |
Why?
|
Review Literature as Topic | 1 | 2016 | 328 | 0.120 |
Why?
|
Preoperative Period | 1 | 2016 | 546 | 0.120 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2005 | 2393 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2023 | 7274 | 0.110 |
Why?
|
Female | 16 | 2023 | 378853 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4935 | 0.100 |
Why?
|
Genetic Testing | 2 | 2022 | 3441 | 0.100 |
Why?
|
Digestive System Surgical Procedures | 1 | 2017 | 568 | 0.100 |
Why?
|
Aged | 12 | 2023 | 162698 | 0.100 |
Why?
|
Genetic Variation | 2 | 2018 | 6539 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2022 | 3504 | 0.100 |
Why?
|
Genomics | 2 | 2018 | 5652 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 2688 | 0.100 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 802 | 0.090 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 1 | 2010 | 26 | 0.090 |
Why?
|
Middle Aged | 14 | 2023 | 212863 | 0.090 |
Why?
|
Male | 14 | 2023 | 349022 | 0.090 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2010 | 84 | 0.090 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2687 | 0.090 |
Why?
|
Lymphatic Metastasis | 1 | 2017 | 2897 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3453 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2022 | 11347 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3051 | 0.080 |
Why?
|
Prognosis | 4 | 2023 | 28901 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3694 | 0.070 |
Why?
|
Neoplasm Staging | 2 | 2017 | 10961 | 0.070 |
Why?
|
Disease Progression | 1 | 2022 | 13237 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2018 | 9387 | 0.060 |
Why?
|
Treatment Outcome | 4 | 2019 | 62693 | 0.060 |
Why?
|
Claudins | 1 | 2023 | 110 | 0.050 |
Why?
|
Adult | 9 | 2021 | 213394 | 0.050 |
Why?
|
Mutation | 2 | 2023 | 29658 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2021 | 57650 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2023 | 8400 | 0.050 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2023 | 643 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17384 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 7897 | 0.040 |
Why?
|
Age Distribution | 1 | 2005 | 2904 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2023 | 825 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2023 | 76631 | 0.040 |
Why?
|
Survival Analysis | 3 | 2020 | 10247 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2005 | 2533 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2023 | 1754 | 0.040 |
Why?
|
Purines | 1 | 2021 | 593 | 0.040 |
Why?
|
Prospective Studies | 4 | 2023 | 53037 | 0.040 |
Why?
|
North America | 1 | 2021 | 1249 | 0.040 |
Why?
|
Aminopyridines | 1 | 2021 | 541 | 0.040 |
Why?
|
Antigens, Bacterial | 1 | 2023 | 1170 | 0.040 |
Why?
|
Radionuclide Imaging | 1 | 2021 | 2028 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2018 | 6871 | 0.040 |
Why?
|
Young Adult | 2 | 2021 | 56255 | 0.040 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1820 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1674 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2016 | 888 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2455 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 588 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2023 | 2015 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2023 | 2039 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2023 | 6610 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 401 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2023 | 38942 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2723 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2270 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 1 | 2023 | 4555 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1522 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2023 | 2861 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4832 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 1994 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1706 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2023 | 3866 | 0.020 |
Why?
|
Medical Oncology | 1 | 2021 | 2217 | 0.020 |
Why?
|
Societies, Medical | 1 | 2021 | 3739 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2030 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2022 | 4663 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3603 | 0.020 |
Why?
|
Vincristine | 1 | 2010 | 1038 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5502 | 0.020 |
Why?
|
Neoplasms | 1 | 2016 | 21507 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12328 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6516 | 0.020 |
Why?
|
Phenotype | 1 | 2023 | 16301 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 21694 | 0.020 |
Why?
|
Prednisone | 1 | 2010 | 1560 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16646 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 21863 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6361 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10142 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10945 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2010 | 2238 | 0.010 |
Why?
|
Pregnancy | 1 | 2005 | 29002 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4211 | 0.010 |
Why?
|
HIV Infections | 1 | 2010 | 16764 | 0.010 |
Why?
|
Doxorubicin | 1 | 2010 | 2218 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 71974 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2020 | 9122 | 0.010 |
Why?
|
Adolescent | 2 | 2010 | 85405 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10534 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 12951 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 40389 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2019 | 6726 | 0.010 |
Why?
|
Signal Transduction | 1 | 2020 | 23355 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81002 | 0.010 |
Why?
|
Risk Assessment | 1 | 2016 | 23294 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2019 | 20676 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168368 | 0.010 |
Why?
|
United States | 1 | 2016 | 69573 | 0.000 |
Why?
|
Child, Preschool | 1 | 2010 | 40802 | 0.000 |
Why?
|
Child | 1 | 2010 | 77033 | 0.000 |
Why?
|
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(93)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_